Foundations Investment Advisors LLC Has $445,000 Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Foundations Investment Advisors LLC reduced its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTXFree Report) by 9.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,300 shares of the company’s stock after selling 11,250 shares during the period. Foundations Investment Advisors LLC owned approximately 0.18% of Black Diamond Therapeutics worth $445,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC bought a new stake in shares of Black Diamond Therapeutics during the 1st quarter valued at $82,000. Acadian Asset Management LLC grew its stake in Black Diamond Therapeutics by 13.8% during the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after buying an additional 20,616 shares in the last quarter. SG Americas Securities LLC bought a new position in Black Diamond Therapeutics in the 2nd quarter valued at about $108,000. Bank of New York Mellon Corp acquired a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at approximately $508,000. Finally, Rhumbline Advisers lifted its holdings in shares of Black Diamond Therapeutics by 10,334.3% during the 2nd quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock worth $218,000 after acquiring an additional 46,401 shares during the period. Institutional investors own 95.47% of the company’s stock.

Analyst Ratings Changes

BDTX has been the subject of several research analyst reports. Piper Sandler boosted their price objective on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, September 23rd. Raymond James started coverage on Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, October 9th.

Check Out Our Latest Report on Black Diamond Therapeutics

Black Diamond Therapeutics Stock Down 2.0 %

Shares of BDTX opened at $2.98 on Friday. The stock has a market cap of $167.63 million, a PE ratio of -1.80 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 12-month low of $1.62 and a 12-month high of $7.66. The business has a 50-day simple moving average of $4.73 and a two-hundred day simple moving average of $5.16.

Black Diamond Therapeutics (NASDAQ:BDTXGet Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, equities research analysts expect that Black Diamond Therapeutics, Inc. will post -1.44 EPS for the current year.

Black Diamond Therapeutics Profile

(Free Report)

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

Recommended Stories

Institutional Ownership by Quarter for Black Diamond Therapeutics (NASDAQ:BDTX)

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.